8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10521 | ODM-207 | BET-IN-4,ODM207 | Epigenetic Reader Domain |
ODM-207 (BET-IN-4) is a potent BRD4 inhibitor. | |||
T2120 | I-BET151 | GSK1210151A | Epigenetic Reader Domain |
I-BET151 (GSK1210151A) (GSK1210151A) is a specific BET inhibitor for BRD2/3/4 (IC50: 0.5/0.25/0.79 μM, in cell-free assays). | |||
T4697 | ABBV-744 | ABBV744 | Epigenetic Reader Domain , HIV Protease |
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2/3/4. It is used in the research on inflammatory diseases, cancer, and AIDS. | |||
T27392 | FT001 | Epigenetic Reader Domain | |
FT001 is a potent, selective and orally available inhibitor of BET Bromodomain with antitumor activity. FT001 inhibited the expression of MYC with the IC50 value of 0.46 μM). FT001 has potent antiproliferative effects ag... | |||
T10522 | BET-IN-6 | Epigenetic Reader Domain | |
BET-IN-6, a ligand with potent and high affinity for inhibiting BRD2/BRD4, plays a crucial role in the synthesis of PROTAC BRD2/BRD4 degrader-1 [1], targeting the protein BRD2/4. | |||
T36574 | GW841819X | GW841819X | |
GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X was a single enantiomer but of undefined chirality at the 4-position of the benzodiazepine ring3. GW841819X and JQ1 were recently d... | |||
T36800 | EN219 | ||
EN219 is a synthetic recruiter of the E3 ubiquitin ligase RNF114.1It binds to cysteine 8 (C8) in the intrinsically disordered region of RNF114 (RNF114-C8; IC50= 470 nM) and inhibits RNF114-induced autoubiquitination and ... | |||
T36103 | TW9 | TW9 | |
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μ... |